Interesting, but do you mind telling me what trial you're talking about? The recent Bay 43-9006 PII data looked pretty good, but I don't know what the precise endpoints were (I know survival is the primary endpoint, but do not know what %). Besides this was interim data, the trial is ongoing. These were very sick patients, so the response they have gotten so far in this population doesn't seem bad at all. Further, the BRAF mutation that this drug targets shows up in a lot of other cancers aside from just kidney cancer, including some lung and breast cancers, so the market is bigger than you're making it out to be.
onyx-pharm.com
Finally, the market has rewarded ONXX for dropping it therapeutic virus programs, which was a very sound and overdue business decision.
Mind you, I can buy the idea that this has gotten ahead of itself, but it has a 50/50 deal with Bayer, so approval for several cancers would be a big chunk. Just playing devil's advocate here.
Further discussion could start with what are the target numbers on those endpoints?
Cheers, Tuck |
